Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Robb

Showing results (581-590 of 731) with videos related to

Pageof 74
Sort By:
Journal of the International AIDS Society|August 29, 2025
High peak viraemia followed by spontaneous HIV-1 control in women living with HIV-1 subtype A1 in East AfricaYifan Li, Bethany L Dearlove, Eric Lewitus, et al.
Ebiomedicine|July 29, 2022
Dissecting drivers of immune activation in chronic HIV-1 infectionHendrik Streeck, Alvino Maestri, Daniel Habermann, et al.
The Journal of Clinical Investigation|May 8, 2025
NK cell activation and CD4 T cell α4β7 expression are associated with susceptibility to HIV-1Kawthar Machmach, Kombo F N'guessan, Rohit Farmer, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Ebiomedicine|November 8, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studyManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Journal of Virology|April 12, 2013
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trialGustavo H Kijak, Sodsai Tovanabutra, Supachai Rerks-Ngarm, et al.
Science Translational Medicine|February 17, 2017
Delayed differentiation of potent effector CD8<sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infectionHiroshi Takata, Supranee Buranapraditkun, Cari Kessing, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targetingManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|May 29, 2019
HIV-1 genetic diversity and demographic characteristics in BulgariaErik Billings, Richard A Heipertz, Tonka Varleva, et al.
Pageof 74

Showing results (581-590 of 731) with videos related to

Sort By:
Pageof 74
Journal of the International AIDS Society|August 29, 2025
High peak viraemia followed by spontaneous HIV-1 control in women living with HIV-1 subtype A1 in East AfricaYifan Li, Bethany L Dearlove, Eric Lewitus, et al.
Ebiomedicine|July 29, 2022
Dissecting drivers of immune activation in chronic HIV-1 infectionHendrik Streeck, Alvino Maestri, Daniel Habermann, et al.
The Journal of Clinical Investigation|May 8, 2025
NK cell activation and CD4 T cell α4β7 expression are associated with susceptibility to HIV-1Kawthar Machmach, Kombo F N'guessan, Rohit Farmer, et al.
Nature Immunology|September 24, 2021
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccinationJeffrey Alan Tomalka, Adam Nicolas Pelletier, Slim Fourati, et al.
Ebiomedicine|November 8, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort studyManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|July 6, 2017
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144Lautaro G Perez, David R Martinez, Allan C deCamp, et al.
Journal of Virology|April 12, 2013
Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trialGustavo H Kijak, Sodsai Tovanabutra, Supachai Rerks-Ngarm, et al.
Science Translational Medicine|February 17, 2017
Delayed differentiation of potent effector CD8<sup>+</sup> T cells reducing viremia and reservoir seeding in acute HIV infectionHiroshi Takata, Supranee Buranapraditkun, Cari Kessing, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targetingManukumar Honnayakanahalli Marichannegowda, Michelle Zemil, Lindsay Wieczorek, et al.
Plos One|May 29, 2019
HIV-1 genetic diversity and demographic characteristics in BulgariaErik Billings, Richard A Heipertz, Tonka Varleva, et al.
Pageof 74